About us

MS Brain Health is calling for a radical change in the management of multiple sclerosis because time matters at every stage of the disease.

The MS Brain Health initiative has emerged from an evidence-based international consensus report, Brain health: time matters in multiple sclerosis, which recommends a strategy to maximize lifelong ‘brain health’.

Click the links below to find out more about:

Steering committee members

Professor Gavin Giovannoni (Chair)

Queen Mary University London, Blizard Institute, Barts and The London School of Medicine and Dentistry, London, UK

G Giovannoni has received consulting fees from AbbVie, Atara Biotherapeutics, Almirall, Biogen, Celgene, GlaxoSmithKline, MedDay Pharmaceuticals, Merck and Company (US), Merck Group (Europe), Novartis, Oxford PharmaGenesis, Roche, Sanofi Genzyme, Synthon, Takeda, Teva Pharmaceutical Industries Ltd., UCB; and grant/research support from Biogen, Sanofi Genzyme, Takeda.

Peer Baneke

Multiple Sclerosis International Federation, London, UK

P Baneke is CEO of the MS international Federation (MSIF). MSIF receives funding from its worldwide member organisations, charitable foundations and the general public. MSIF receives further funding from the following healthcare companies: Biogen-Idec, Celgene, Sanofi Genzyme, Merck, Med-Day, Roche, Teva and Will-Pharma.

Professor Helmut Butzkueven

Alfred Health and Eastern Health, Monash University, Melbourne, Australia

H Butzkueven has received consulting fees from Biogen, Genzyme, Merck, Novartis and Oxford PharmaGenesis; and grant/research support from Genzyme, Merck and Novartis.

Jodi Haartsen

Eastern Health, Victoria, Australia

J Haartsen has received assistance for travel for conferences, speaker honorarium and fees from Biogen, Merck, Novartis, Oxford PharmaGenesis and Roche.

Professor Jeremy Hobart

Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK

J Hobart has received consulting fees, honoraria, support to attend meetings or research support from Acorda, Asubio, Bayer Schering, Biogen Idec, F. Hoffmann-La Roche, Genzyme, Merck Serono, Novartis, Oxford PharmaGenesis and Teva.

Dr Gisela Kobelt

European Health Economics, Mulhouse, France

G Kobelt has received consulting fees from Almirall, Bayer, Biogen, Merck Serono, Novartis, Oxford PharmaGenesis, Roche, Sanofi Genzyme and Teva.

Christoph Thalheim

European Multiple Sclerosis Platform, Brussels, Belgium

C Thalheim has acted as a speaker and adviser on non-product-specific subjects for Almirall, Bayer, Biogen, GSK, Novartis, Roche, Synthon, Takeda and Teva; and has received consulting fees from Gruenenthal and Oxford PharmaGenesis.

Professor Anthony Traboulsee

University of British Columbia, Vancouver, Canada

A Traboulsee has received consulting fees from Biogen, Genzyme, Novartis, Oxford PharmaGenesis, Roche and Teva; and has received grant/research support as a PI on clinical trials with Biogen, Chugai, Genzyme and Roche.

Professor Timothy Vollmer

University of Colorado Health Sciences Center, Colorado, USA

T Vollmer has received consulting fees from Academic CME, Alcimed, Anthem Blue Cross, Biogen IDEC, Celgene, Dleara Lawyers, Epigene, Genentech/Roche, GLG Consulting, Novartis, Ohio Health, Rocky Mountain MS Center, TG Therapeutics, Inc., Teva Neuroscience and Topaz Therapeutics; and has received grant/research support from Actelion, Biogen, NIH/NINDS, Teva Neuroscience, TG Therapeutics Inc., Genentech/Roche, Rocky Mountain MS Center and UT Southwestern.

Professor Dr med Tjalf Ziemssen

University Clinic Carl Gustav Carus Dresden, Dresden, Germany

T Ziemssen has received personal compensation for participating on advisory boards, trial steering committees and data and safety monitoring committees, as well as for scientific talks and project support, from Almirall, Bayer HealthCare, Biogen Idec, Celgene, Merck Serono, Novartis, Roche, Sanofi Genzyme and Teva.